Leadership
The COPDforum leadership is comprised of renowned researchers/clinicians in COPD, who have contributed significantly
to the developments in this field. This global group represents some of the world's thought leaders in this area,
who are prominent in respiratory publications, international and local societies and research initiatives. Click on the
links below to learn more about the COPDforum leadership.
Leadership
Marc Miravitlles
MD
Spain
Place of work
Institut Clínic del Tòrax, Hospital Clinic Barcelona.
Experience
Marc Miravitlles is a Chest Physician and Senior Researcher in the Department of Pneumology at the Hospital Clinic, Barcelona, Spain. His primary research interests include chronic obstructive pulmonary disease (COPD), chronic bronchitis, alpha-1-antitripsin deficiency, lung defence mechanisms and respiratory infections.
Dr Miravitlles serves on various medical committees and is a member of numerous professional societies, including the Spanish Society of Pneumology and Thoracic Surgery (SEPAR), which he served as Secretary from 1999 until 2003. Since 2006, he has been responsible, within SEPAR, for international relationships. Currently, he has been elected Chair of the Respiratory Infections Group of the European Respiratory Society (ERS) and was a member of the ERS task force in the redaction of the American Thoracic Society/European Respiratory Society task force on outcomes of COPD (ERJ 2008). He has acted as a consultant for the development of the Spanish, Central American, Latin American and Canadian guidelines on the management of exacerbations of COPD and has participated in the development of Spanish and Brazilian guidelines on the management of COPD. He serves as the Co-ordinator of the Spanish Registry of Patients with AAT deficiency and is the Spanish Representative for the Alpha-1 International Registry (AIR).
Dr Miravitlles has published over 100 papers including the American Journal of Respiratory and Critical Care Medicine, European Respiratory Journal, Thorax, and Chest. A sample of his most recent papers is listed below.
Recent publications
Miravitlles M, Anzueto A. Moxifloxacin: a respiratory fluoroquinolone. Expert Opin Pharmacother 2008;9(10):1755–72.
Llor C, Molina J, Naberan K, Cots JM, Ros F, Miravitlles M; EVOCA study group. Exacerbations worsen the quality of life of chronic obstructive pulmonary disease patients in primary healthcare. Int J Clin Pract 2008;62(4):585–92.
Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Mölken MP, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF; American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31(2):416–69.
Lara B, de la Roza C, Vilà S, Vidal R, Miravitlles M. Development and results of the Spanish registry of patients with alpha-1-antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis 2007;2(3):393–8.
Miravitlles M. Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD. Int J Chron Obstruct Pulmon Dis 2007;2(3):191–204.
Miravitlles M, Celli B, Anzueto A. Antibiotics for chronic bronchitis: a meta-analysis that speaks only four languages. Eur Respir J 2007;30(4):815; author reply 815-6. Erratum in: Eur Respir J 2007;30(6):1236.
Miravitlles M, Morera J. It's time for an aetiology-based definition of chronic obstructive pulmonary disease. Respirology 2007;12(3):317–9.
Miravitlles M, Zalacain R, Murio C, Ferrer M, Alvarez-Sala JL, Masa JF, Verea H, Ros F, Vidal R; on behalf of the IMPAC Study Group. Speed of recovery from acute exacerbations of chronic obstructive pulmonary disease after treatment with antimicrobials : results of a two-year study. Clin Drug Investig 2003;23(7):439–50.
Llor C, Miravitlles M. More evidence is required for short-term treatment of exacerbations of chronic obstructive pulmonary disease: 3 days or no antibiotic at all? Clin Microbiol Infect 2007;13(7):748–9.
Miravitlles M, de la Roza C, Naberan K, Lamban M, Gobartt E, Martin A. Use of spirometry and patterns of prescribing in COPD in primary care. Respir Med 2007;101(8):1753–60.
Rutten-van Mölken MP, Oostenbrink JB, Miravitlles M, Monz BU. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ 2007;8(2):123–35.